Synergistic Neuroprotective Composition for α-Synuclein Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases such as Parkinson's and Alzheimer's do not effectively halt or slow the progression of these conditions, and existing studies on coffee consumption's benefits have not fully explored the mechanisms behind its potential neuroprotective effects.
Innovation Solution
A synergistic neuroprotective composition combining caffeine and a long chain fatty acyl tryptamide, specifically eicosanoyl-5-hydroxytryptamide, which is administered in specific ratios and forms to reduce α-synuclein phosphorylation and aggregation, inflammation, and improve neuronal health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current therapies (levodopa, dopamine agonists, MAO inhibitors, etc.) are administered to modify neural transmissions, then symptoms of Parkinson's disease are suppressed, but the underlying progression of the neurodegenerative process is not halted or slowed
Solution Approach 1:
The patent extracts and addresses the underlying cause of neurodegeneration (α-synuclein aggregation and phosphorylation) rather than just treating symptoms. The composition targets the root pathological mechanisms by reducing α-synuclein aggregation and phosphorylation, thereby addressing the fundamental disease progression while symptom management is handled by conventional therapies.
Solution Approach 2:
The patent uses a composite neuroprotective composition containing multiple components (caffeine, long-chain fatty acyl tryptamide, and other cofactors) that work synergistically to provide neuroprotection. This composite approach addresses multiple pathological mechanisms simultaneously, including reducing α-synuclein aggregation, inhibiting phosphorylation, and providing antioxidant protection, thereby controlling disease progression more effectively than single-agent therapies.
2Reliability
If caffeine alone is used as the neuroprotective agent, then some protective effect is observed, but the neuroprotection is insufficient compared to synergistic compositions
Solution Approach 1:
The patent merges caffeine with long-chain fatty acyl tryptamide and other cofactors to create a synergistic composition. The combination of these components produces a neuroprotective effect greater than the sum of individual effects, as each component targets different aspects of neurodegeneration (α-synuclein aggregation, phosphorylation, oxidative stress) and they work together to provide comprehensive protection.
Solution Approach 2:
The neuroprotective composition is designed to perform multiple functions simultaneously: reducing α-synuclein aggregation, inhibiting phosphorylation, providing antioxidant protection, and supporting neuronal health. This multi-functional approach allows a single composition to address various pathological mechanisms of neurodegeneration, making it more effective than single-agent therapies while maintaining practical usability.
3Reliability
If tryptamides are used to modulate protein phosphatase 2A (PP2A), then dephosphorylation of α-synuclein is enhanced and cognitive functions improve, but the neuroprotection is not sufficient without additional components
Solution Approach 1:
The patent uses long-chain fatty acyl tryptamide as an intermediary that modulates protein phosphatase 2A (PP2A) activity to enhance dephosphorylation of α-synuclein. This intermediary mechanism addresses the phosphorylation aspect of neurodegeneration while the accompanying caffeine and other cofactors address aggregation and oxidative stress, creating a balanced and complete neuroprotective strategy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively prevents or slows neurodegeneration by reducing α-synuclein aggregates, inflammation, and enhancing neuronal protection, offering improved neuroprotection beyond what caffeine or tryptamides can achieve alone.
Implementation Method 1
They have been previously discovered to modulate protein phosphatase 2A (PP2A), which is able to dephosphorylate α-synuclein
Implementation Method 2
reduce α-synuclein phosphorylation and aggregation
Data Source
AI summary
A neuroprotective compositions containing caffeine or a caffeine analogue and a long chain fatty acyl tryptamide with an aliphatic chain having 16 to 22 carbons linked to a tryptamine, wherein the composition contains from at least 1.5 mg to 600 mg of caffeine per serving or unit dosage of the composition; from at least 0.5 mg to 300 mg of the long chain fatty acyl tryptamide per serving or unit dosage of the composition; and the ratio of long chain fatty acyl tryptamide to caffeine is from 1:1200 to 200:1. Methods are also disclosed for treating or preventing cognitive and movement deficits of a disease, condition or disorder or neurological deterioration that use the disclosed neuroprotective compositions.